The position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists - Comments on the current therapy for neovascular AMD;Konsenspapier der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augenärzte - Stellungnahme zur aktuellen therapie der neovaskulären AMD

Klinische Monatsblatter fur Augenheilkunde

Volumn 222, Issue 5, 2005, Pages 381-388

  Pauleikhoff, D ^a   Bornfeld, N ^b   Gabel, V P ^c   Holz, F ^d   Roider, H ^e  

^a ST FRANZISKUS HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Age related macular degeneration; Anti angiogenetic therapy; Photodynamic therapy

Indexed keywords

ANECORTAVE; ANGIOGENESIS INHIBITOR; BENZOPORPHYRIN DERIVATIVE; CORTICOSTEROID; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; GOOD CLINICAL PRACTICE; HUMAN; LASER COAGULATION; MEDICAL SPECIALIST; MONOTHERAPY; ORGANIZATION; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL ACUITY;

CHOROIDAL NEOVASCULARIZATION; HUMANS; LASER SURGERY; MACULAR DEGENERATION; OPHTHALMOLOGIC SURGICAL PROCEDURES; PHOTOCHEMOTHERAPY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 20444457089     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-858225     Document Type: Review

References (17)

1. Bressler SB, Pieramici DJ, Koester JM et al. Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) Investigation: outcomes potentially relevant to management. TAP Report No. 6. Arch Ophthalmol 2004; 122: 325-329
2. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, Verteporfin In Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using Verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002; 22: 6-18
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with Verteporfin: two-year results of 2 randomized clinical trials-TAP Report 2. Arch Ophthalmol 2001; 119: 198-207
4. Verteporfin In Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 2001; 131: 541-560
5. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration-TAP and VIP Report 1. Am J Ophthalmol 2003; 136: 407-418
6. Rosenfeld PJ. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Visual outcomes in patients with minimally classic choroidal neovascularization (CNV): rationale for the Visudyne in Minimally classic CNV (VIM) Trial. Invest Ophthalmol Vis Sci 2001; 42: S512
7. Danis RP, Ciulla TA, Pratt LM et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244-250
8. Gillies MC, Simpson JM, Luo W et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003; 121: 667-673
9. Jonas JB, Degenring RF, Kreissig I et al. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye 2004
10. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110: 1517-1525
11. Rechtman E, Danis RP, Pratt LM et al. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004; 88: 344-347
12. Gragoudas ES. VEGF inhibition study in ocular neovascularization-1 (VISION-1): Efficacy results from phase II/III Macugen (pegaptanib sodium) clinical trials. Invest Ophthalmol Vis Sci 2004: E-Abstract 2364
13. Schwartz SD. Anti-VEGF: Eyetech-Macugen. Data taken from presentation at 2004 AAO Retina Subspeciality Day.
14. Gragoudas ES, Adamis AP, Cunningham ET Jr et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 30 (351): 2805-2816
15. Heier JS. Review of Lucentis™ (ranibizumab, rhuFab V2) phase I/II trial results: 6-month treatment of exudative AMD. Invest Ophthalmol Vis Sci 2004: E-Abstract 1109
16. Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003; 110: 2372-2383
17. Slakter JS. Anecortave Acetate Clinical Study Group. Anecortave Acetate in the treatment of Age-Related Macular Degeneration (AMD). Invest Ophthalmol Vis Sci 2004: E-Abstract 1110